Skip to main content
Top
Published in: Neurology and Therapy 2/2019

Open Access 01-12-2019 | Multiple Sclerosis | Commentary

Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression

Authors: Jeri Burtchell, Kristen Fetty, Katelyn Miller, Kit Minden, Daniel Kantor

Published in: Neurology and Therapy | Issue 2/2019

Login to get access

Abstract

Multiple sclerosis (MS) is a chronic progressive disease and many patients transition from an initial relapsing–remitting course to a secondary progressive pattern. Accurate classification of disease status is critical to ensure that patients are treated appropriately and kept informed of their prognosis. Consensus terms defining the different forms of MS are available but were developed primarily for healthcare professionals (HCPs) and may be of limited value to patients. This article provides direct insights from four patients with MS, at different points in their disease trajectory, regarding their understanding of, and attitudes toward, MS progression. We also examine the utility of the current classification systems from the perspectives of patients and HCPs. Responses collected during in-depth, structured interviews and questionnaires portrayed the difficulties patients face accepting their MS diagnosis and treatment, revealed how understanding of the term “disease progression” varies considerably, and highlighted the challenges surrounding the period of transition to secondary progressive MS (SPMS). The terms describing different MS types were considered confusing and can make patients feel “compartmentalized” or “labeled”. Patients also struggled to relate these terms to their reality of living with MS, were reluctant to discuss progression with their HCPs, and feared being diagnosed with SPMS owing to concerns about treatment access. These insights highlight the need to develop patient-friendly language to describe MS progression; it may also be preferable for HCPs to describe MS as a disease spectrum in discussions with their patients.

Funding

Novartis Pharmaceuticals Corporation.

Plain Language Summary

Plain language summary available for this article.
Literature
1.
go back to reference Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907–11.PubMedCrossRef Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907–11.PubMedCrossRef
2.
5.
go back to reference McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–7.PubMedCrossRef McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–7.PubMedCrossRef
6.
go back to reference Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–6.PubMedCrossRef Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–6.PubMedCrossRef
7.
go back to reference Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.PubMedPubMedCentralCrossRef Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.PubMedPubMedCentralCrossRef
8.
go back to reference Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.PubMedCrossRef Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.PubMedCrossRef
9.
go back to reference Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009;15:627–31.PubMedCrossRef Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009;15:627–31.PubMedCrossRef
10.
go back to reference Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59:1006–10.PubMedCrossRef Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59:1006–10.PubMedCrossRef
11.
go back to reference Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997;3:43–6.PubMedCrossRef Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997;3:43–6.PubMedCrossRef
12.
go back to reference Antel J, Antel S, Caramanos Z, Arnold DL, Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 2012;123:627–38.PubMedCrossRef Antel J, Antel S, Caramanos Z, Arnold DL, Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 2012;123:627–38.PubMedCrossRef
13.
go back to reference Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129:584–94.PubMedCrossRef Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129:584–94.PubMedCrossRef
14.
go back to reference Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1039–43.PubMedCrossRef Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1039–43.PubMedCrossRef
15.
go back to reference Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:67–75.PubMedCrossRef Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:67–75.PubMedCrossRef
16.
go back to reference Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139:2395–405.PubMedCrossRef Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139:2395–405.PubMedCrossRef
17.
go back to reference Plantone D, De Angelis F, Doshi A, Chataway J. Secondary progressive multiple sclerosis: definition and measurement. CNS Drugs. 2016;30:517–26.PubMedCrossRef Plantone D, De Angelis F, Doshi A, Chataway J. Secondary progressive multiple sclerosis: definition and measurement. CNS Drugs. 2016;30:517–26.PubMedCrossRef
19.
go back to reference Davies F, Wood F, Brain KE, et al. The transition to secondary progressive multiple sclerosis: an exploratory qualitative study of health professionals’ experiences. Int J MS Care. 2016;18:257–64.PubMedPubMedCentralCrossRef Davies F, Wood F, Brain KE, et al. The transition to secondary progressive multiple sclerosis: an exploratory qualitative study of health professionals’ experiences. Int J MS Care. 2016;18:257–64.PubMedPubMedCentralCrossRef
20.
go back to reference Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20:1654–7.PubMedCrossRef Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20:1654–7.PubMedCrossRef
21.
go back to reference Nandoskar A, Raffel J, Scalfari AS, Friede T, Nicholas RS. Pharmacological approaches to the management of secondary progressive multiple sclerosis. Drugs. 2017;77:885–910.PubMedCrossRef Nandoskar A, Raffel J, Scalfari AS, Friede T, Nicholas RS. Pharmacological approaches to the management of secondary progressive multiple sclerosis. Drugs. 2017;77:885–910.PubMedCrossRef
22.
go back to reference Ziemssen T, Simsek D, Lahoz R, di Cantogno VE. Development of a screening tool to support identification of patients with secondary progressive multiple sclerosis (SPMS). Value Health. 2015;18:A763.CrossRef Ziemssen T, Simsek D, Lahoz R, di Cantogno VE. Development of a screening tool to support identification of patients with secondary progressive multiple sclerosis (SPMS). Value Health. 2015;18:A763.CrossRef
23.
go back to reference Leddy S, Hadavi S, McCarren A, Giovannoni G, Dobson R. Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. J Neurol. 2013;260:2505–10.PubMedCrossRef Leddy S, Hadavi S, McCarren A, Giovannoni G, Dobson R. Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. J Neurol. 2013;260:2505–10.PubMedCrossRef
24.
go back to reference Kragt JJ, Nielsen JM, van der Linden FA, Polman CH, Uitdehaag BM. Disease progression in multiple sclerosis: combining physicians’ and patients’ perspectives? Mult Scler. 2011;17:234–40.PubMedCrossRef Kragt JJ, Nielsen JM, van der Linden FA, Polman CH, Uitdehaag BM. Disease progression in multiple sclerosis: combining physicians’ and patients’ perspectives? Mult Scler. 2011;17:234–40.PubMedCrossRef
25.
go back to reference Dickens AM, Larkin JR, Griffin JL, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology. 2014;83:1492–9.PubMedPubMedCentralCrossRef Dickens AM, Larkin JR, Griffin JL, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology. 2014;83:1492–9.PubMedPubMedCentralCrossRef
26.
go back to reference Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nerman O, Andersen O. The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol. 2015;262:1148–63.PubMedCrossRef Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nerman O, Andersen O. The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol. 2015;262:1148–63.PubMedCrossRef
27.
go back to reference Akhtar S, Alroughani R, Ahmed SF, Al-Hashel JY. Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait. Mult Scler. 2016;22:1086–93.PubMedCrossRef Akhtar S, Alroughani R, Ahmed SF, Al-Hashel JY. Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait. Mult Scler. 2016;22:1086–93.PubMedCrossRef
28.
go back to reference Skoog B, Tedeholm H, Runmarker B, Oden A, Andersen O. Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Relat Disord. 2014;3:584–92.PubMedCrossRef Skoog B, Tedeholm H, Runmarker B, Oden A, Andersen O. Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Relat Disord. 2014;3:584–92.PubMedCrossRef
29.
go back to reference Dennison L, Moss-Morris R, Chalder T. A review of psychological correlates of adjustment in patients with multiple sclerosis. Clin Psychol Rev. 2009;29:141–53.PubMedCrossRef Dennison L, Moss-Morris R, Chalder T. A review of psychological correlates of adjustment in patients with multiple sclerosis. Clin Psychol Rev. 2009;29:141–53.PubMedCrossRef
30.
go back to reference Dennison L, McCloy Smith E, Bradbury K, Galea I. How do people with multiple sclerosis experience prognostic uncertainty and prognosis communication? A qualitative study. PLoS One. 2016;11:e0158982.PubMedPubMedCentralCrossRef Dennison L, McCloy Smith E, Bradbury K, Galea I. How do people with multiple sclerosis experience prognostic uncertainty and prognosis communication? A qualitative study. PLoS One. 2016;11:e0158982.PubMedPubMedCentralCrossRef
31.
go back to reference Kantor D, Bright JR, Burtchell J. Perspectives from the patient and the healthcare professional in multiple sclerosis: social media and participatory medicine. Neurol Ther. 2018;7:37–49.PubMedCrossRef Kantor D, Bright JR, Burtchell J. Perspectives from the patient and the healthcare professional in multiple sclerosis: social media and participatory medicine. Neurol Ther. 2018;7:37–49.PubMedCrossRef
32.
go back to reference Kantor D, Bright JR, Burtchell J. Perspectives from the patient and the healthcare professional in multiple sclerosis: social media and patient education. Neurol Ther. 2018;7:23–36.PubMedCrossRef Kantor D, Bright JR, Burtchell J. Perspectives from the patient and the healthcare professional in multiple sclerosis: social media and patient education. Neurol Ther. 2018;7:23–36.PubMedCrossRef
34.
go back to reference O’Loughlin E, Hourihan S, Chataway J, Playford ED, Riazi A. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. Disabil Rehabil. 2017;39:1821–8.PubMedCrossRef O’Loughlin E, Hourihan S, Chataway J, Playford ED, Riazi A. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. Disabil Rehabil. 2017;39:1821–8.PubMedCrossRef
36.
go back to reference Giovannetti AM, Giordano A, Pietrolongo E, et al. Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open. 2017;7:e017254.PubMedPubMedCentralCrossRef Giovannetti AM, Giordano A, Pietrolongo E, et al. Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open. 2017;7:e017254.PubMedPubMedCentralCrossRef
39.
go back to reference Davies F, Edwards A, Brain K, et al. ‘You are just left to get on with it’: qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis. BMJ Open. 2015;5:e007674.PubMedPubMedCentralCrossRef Davies F, Edwards A, Brain K, et al. ‘You are just left to get on with it’: qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis. BMJ Open. 2015;5:e007674.PubMedPubMedCentralCrossRef
41.
go back to reference Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–88.PubMedCrossRef Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–88.PubMedCrossRef
42.
go back to reference Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263–73.PubMedCrossRef Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263–73.PubMedCrossRef
43.
go back to reference Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14:194–207.PubMedCrossRef Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14:194–207.PubMedCrossRef
44.
go back to reference Lorscheider J, Jokubaitis VG, Spelman T, et al. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology. 2017;89:1050–9.PubMedPubMedCentralCrossRef Lorscheider J, Jokubaitis VG, Spelman T, et al. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology. 2017;89:1050–9.PubMedPubMedCentralCrossRef
47.
go back to reference Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler. 2013;19:765–74.PubMedPubMedCentralCrossRef Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler. 2013;19:765–74.PubMedPubMedCentralCrossRef
48.
go back to reference D’Amico E, Ziemssen T, Cottone S. To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. Expert Rev Neurother. 2017;17:847–9.PubMedCrossRef D’Amico E, Ziemssen T, Cottone S. To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. Expert Rev Neurother. 2017;17:847–9.PubMedCrossRef
49.
go back to reference Coetzee T, Zaratin P, Gleason TL. Overcoming barriers in progressive multiple sclerosis research. Lancet Neurol. 2015;14:132–3.PubMedCrossRef Coetzee T, Zaratin P, Gleason TL. Overcoming barriers in progressive multiple sclerosis research. Lancet Neurol. 2015;14:132–3.PubMedCrossRef
50.
go back to reference Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–93.PubMedCrossRef Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–93.PubMedCrossRef
51.
go back to reference Zeller D, Classen J. Plasticity of the motor system in multiple sclerosis. Neuroscience. 2014;283:222–30.PubMedCrossRef Zeller D, Classen J. Plasticity of the motor system in multiple sclerosis. Neuroscience. 2014;283:222–30.PubMedCrossRef
52.
go back to reference Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14:208–23.PubMedPubMedCentralCrossRef Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14:208–23.PubMedPubMedCentralCrossRef
53.
go back to reference Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.PubMedCrossRef Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.PubMedCrossRef
54.
go back to reference Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler. 2012;18:1534–40.PubMedPubMedCentralCrossRef Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler. 2012;18:1534–40.PubMedPubMedCentralCrossRef
57.
go back to reference Borreani C, Bianchi E, Pietrolongo E, et al. Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. PLoS One. 2014;9:e109679.PubMedPubMedCentralCrossRef Borreani C, Bianchi E, Pietrolongo E, et al. Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. PLoS One. 2014;9:e109679.PubMedPubMedCentralCrossRef
58.
go back to reference Pilutti LA, Paulseth JE, Dove C, Jiang S, Rathbone MP, Hicks AL. Exercise training in progressive multiple sclerosis: a comparison of recumbent stepping and body weight-supported treadmill training. Int J MS Care. 2016;18:221–9.PubMedPubMedCentralCrossRef Pilutti LA, Paulseth JE, Dove C, Jiang S, Rathbone MP, Hicks AL. Exercise training in progressive multiple sclerosis: a comparison of recumbent stepping and body weight-supported treadmill training. Int J MS Care. 2016;18:221–9.PubMedPubMedCentralCrossRef
59.
go back to reference Straudi S, Fanciullacci C, Martinuzzi C, et al. The effects of robot-assisted gait training in progressive multiple sclerosis: a randomized controlled trial. Mult Scler. 2016;22:373–84.PubMedCrossRef Straudi S, Fanciullacci C, Martinuzzi C, et al. The effects of robot-assisted gait training in progressive multiple sclerosis: a randomized controlled trial. Mult Scler. 2016;22:373–84.PubMedCrossRef
60.
go back to reference Taylor P, Barrett C, Mann G, Wareham W, Swain I. A feasibility study to investigate the effect of functional electrical stimulation and physiotherapy exercise on the quality of gait of people with multiple sclerosis. Neuromodulation. 2014;17:75–84 (discussion).PubMedCrossRef Taylor P, Barrett C, Mann G, Wareham W, Swain I. A feasibility study to investigate the effect of functional electrical stimulation and physiotherapy exercise on the quality of gait of people with multiple sclerosis. Neuromodulation. 2014;17:75–84 (discussion).PubMedCrossRef
61.
go back to reference Esnouf JE, Taylor PN, Mann GE, Barrett CL. Impact on activities of daily living using a functional electrical stimulation device to improve dropped foot in people with multiple sclerosis, measured by the Canadian Occupational Performance Measure. Mult Scler. 2010;16:1141–7.PubMedCrossRef Esnouf JE, Taylor PN, Mann GE, Barrett CL. Impact on activities of daily living using a functional electrical stimulation device to improve dropped foot in people with multiple sclerosis, measured by the Canadian Occupational Performance Measure. Mult Scler. 2010;16:1141–7.PubMedCrossRef
62.
go back to reference Ratchford JN, Shore W, Hammond ER, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. NeuroRehabilitation. 2010;27:121–8.PubMedCrossRef Ratchford JN, Shore W, Hammond ER, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. NeuroRehabilitation. 2010;27:121–8.PubMedCrossRef
63.
go back to reference Pilutti LA, Lelli DA, Paulseth JE, et al. Effects of 12 weeks of supported treadmill training on functional ability and quality of life in progressive multiple sclerosis: a pilot study. Arch Phys Med Rehabil. 2011;92:31–6.PubMedCrossRef Pilutti LA, Lelli DA, Paulseth JE, et al. Effects of 12 weeks of supported treadmill training on functional ability and quality of life in progressive multiple sclerosis: a pilot study. Arch Phys Med Rehabil. 2011;92:31–6.PubMedCrossRef
64.
go back to reference Donnellan CP, Shanley J. Comparison of the effect of two types of acupuncture on quality of life in secondary progressive multiple sclerosis: a preliminary single-blind randomized controlled trial. Clin Rehabil. 2008;22:195–205.PubMedCrossRef Donnellan CP, Shanley J. Comparison of the effect of two types of acupuncture on quality of life in secondary progressive multiple sclerosis: a preliminary single-blind randomized controlled trial. Clin Rehabil. 2008;22:195–205.PubMedCrossRef
65.
go back to reference Saccardi R, Mancardi GL, Solari A, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. 2005;105:2601–7.PubMedCrossRef Saccardi R, Mancardi GL, Solari A, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. 2005;105:2601–7.PubMedCrossRef
66.
go back to reference Vanage SM, Gilbertson KK, Mathiowetz V. Effects of an energy conservation course on fatigue impact for persons with progressive multiple sclerosis. Am J Occup Ther. 2003;57:315–23.PubMedCrossRef Vanage SM, Gilbertson KK, Mathiowetz V. Effects of an energy conservation course on fatigue impact for persons with progressive multiple sclerosis. Am J Occup Ther. 2003;57:315–23.PubMedCrossRef
67.
go back to reference Gillson G, Wright JV, DeLack E, Ballasiotes G. Transdermal histamine in multiple sclerosis: part one—clinical experience. Altern Med Rev. 1999;4:424–8.PubMed Gillson G, Wright JV, DeLack E, Ballasiotes G. Transdermal histamine in multiple sclerosis: part one—clinical experience. Altern Med Rev. 1999;4:424–8.PubMed
68.
go back to reference Di Fabio RP, Choi T, Soderberg J, Hansen CR. Health-related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther. 1997;77:1704–16.PubMedCrossRef Di Fabio RP, Choi T, Soderberg J, Hansen CR. Health-related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther. 1997;77:1704–16.PubMedCrossRef
69.
go back to reference Lee JE, Bisht B, Hall MJ, et al. A multimodal, nonpharmacologic intervention improves mood and cognitive function in people with multiple sclerosis. J Am Coll Nutr. 2017;36:150–68.PubMedCrossRef Lee JE, Bisht B, Hall MJ, et al. A multimodal, nonpharmacologic intervention improves mood and cognitive function in people with multiple sclerosis. J Am Coll Nutr. 2017;36:150–68.PubMedCrossRef
70.
go back to reference Meneghetti G, Sparta S, Rusca F, et al. Hyperbaric oxygen therapy in the treatment of multiple sclerosis. A clinical and electrophysiological study in a 2 year follow-up. Riv Neurol. 1990;60:67–71.PubMed Meneghetti G, Sparta S, Rusca F, et al. Hyperbaric oxygen therapy in the treatment of multiple sclerosis. A clinical and electrophysiological study in a 2 year follow-up. Riv Neurol. 1990;60:67–71.PubMed
75.
go back to reference Siva A. The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg. 2006;108:333–8.PubMedCrossRef Siva A. The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg. 2006;108:333–8.PubMedCrossRef
76.
go back to reference Haegert DG. Clinical multiple sclerosis occurs at one end of a spectrum of CNS pathology: a modified threshold liability model leads to new ways of thinking about the cause of clinical multiple sclerosis. Med Hypotheses. 2005;65:232–7.PubMedCrossRef Haegert DG. Clinical multiple sclerosis occurs at one end of a spectrum of CNS pathology: a modified threshold liability model leads to new ways of thinking about the cause of clinical multiple sclerosis. Med Hypotheses. 2005;65:232–7.PubMedCrossRef
77.
go back to reference Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–57.PubMedPubMedCentralCrossRef Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–57.PubMedPubMedCentralCrossRef
80.
go back to reference Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273–9.PubMedCrossRef Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273–9.PubMedCrossRef
Metadata
Title
Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression
Authors
Jeri Burtchell
Kristen Fetty
Katelyn Miller
Kit Minden
Daniel Kantor
Publication date
01-12-2019
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 2/2019
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-019-0141-4

Other articles of this Issue 2/2019

Neurology and Therapy 2/2019 Go to the issue